Open AccessSerum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy
Author(s) -
Hayashi Tomohiro,
Nukui Takamasa,
Piao JinLan,
Sugimoto Tomoyuki,
Anada Ryoko,
Matsuda Noriyuki,
Yamamoto Mamoru,
Konishi Hirofumi,
Dougu Nobuhiro,
Nakatsuji Yuji
Publication year - 2021
Publication title -
brain and behavior
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.915
H-Index - 41
ISSN - 2162-3279
DOI - 10.1002/brb3.2084
Subject(s) - chronic inflammatory demyelinating polyneuropathy , medicine , biomarker , polyradiculoneuropathy , gastroenterology , polyneuropathy , disease , peripheral neuropathy , antibody , immunology , guillain barre syndrome , endocrinology , diabetes mellitus , biochemistry , chemistry
Objectives Neurofilament light chain (NfL) levels have been suggested as reflecting axonal damage in various inflammatory and neurodegenerative disorders, including acquired peripheral neuropathies. We aimed to investigate if serum NfL (sNfL) levels can be a biomarker of disease activity and treatment response in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Materials and methods The sNfL levels of eleven newly diagnosed patients with CIDP were retrospectively assayed and compared with seven healthy volunteers. The levels were assayed before and after intravenous immunoglobulin treatment in patients with CIDP and were also assayed in the remission period. Results Baseline sNfL levels in patients with CIDP before treatment were significantly higher than those in healthy controls. The levels significantly decreased overtime after one month of treatment and in remission period. There were significant negative correlations between the sNfL levels and the disease duration (the interval between the onset of the disease and the time of sampling), and weak correlations between the sNfL levels and overall neuropathy limitations scale. Conclusions sNfL may be a potential biomarker reflecting the disease activity in patients with CIDP.